Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3662 | 1.00 | — | — | |
| SCHEMBL2531259 | 1.00 | TP53 (0.61) | TP53SLC7A5ALDH1A1TSHRLMNA | |
| SCHEMBL17767367 | 1.00 | TP53 (0.61) | TP53SLC7A5ALDH1A1TSHRLMNA | |
| SCHEMBL5940223 | 1.00 | TP53 (0.61) | TP53SLC7A5ALDH1A1TSHRLMNA | |
| SCHEMBL10857351 | 1.00 | — | — | |
| Hydrogen Peroxide SCHEMBL28852493 | 1.00 | — | — | |
| SCHEMBL17767389 | 1.00 | TP53 (0.61) | TP53SLC7A5ALDH1A1TSHRLMNA | |
| SCHEMBL4640114 | 1.00 | TP53 (0.61) | TP53SLC7A5ALDH1A1TSHRLMNA | |
| SCHEMBL405938 | 1.00 | TP53 (0.61) | TP53SLC7A5ALDH1A1TSHRLMNA | |
| SCHEMBL1331326 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2014-03-20 | — | — | US | claimed |
| US-20100204162-A1 | SUBSTRATE REDUCTION THERAPY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-08-12 | — | — | US | claimed |
| EP-2182936-A2 | SUBSTRATE REDUCTION THERAPY | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2010-05-12 | — | — | EP | claimed |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2010-01-28 | — | — | US | claimed |
| WO-2009141627-A1 | TREATING NIEMANN-PICK DISEASE TYPE C AND RELATED DISORDERS BY ELEVATING INTRACELLULAR CALCIUM | ISIS INNOVATION LIMITED (GB) | 2009-11-26 | — | — | WO | claimed |
| EP-2051708-A2 | EPITOPE REDUCTION THERAPY | ISIS Innovation Limited (GB) | 2009-04-29 | — | — | EP | claimed |
| WO-2009001097-A2 | SUBSTRATE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2008-12-31 | — | — | WO | claimed |
| WO-2008012555-A2 | EPITOPE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2008-01-31 | — | — | WO | claimed |
| EP-0367748-B1 | Novel antiviral compounds | SEARLE & CO (US) | 1995-01-25 | — | — | EP | claimed |
| US-5310745-A | Acylated derivatives of 1,5-dideoxy-1,5-imino-D-glucitol, AIDS | G. D. SEARLE & CO. (US) | 1994-05-10 | — | — | US | claimed |
| US-5003072-A | Viricides | G. D. SEARLE & CO. (US) | 1991-03-26 | — | — | US | claimed |
| EP-0367748-A2 | Novel antiviral compounds | G.D. SEARLE & COMPANY (US) | 1990-05-09 | — | — | EP | claimed |
| EP-2182936-B1 | SUBSTRATE REDUCTION THERAPY | THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIV OF OXFORD (GB) | 2020-04-01 | — | — | EP | disclosed |
| US-20180125796-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-05-10 | — | — | US | disclosed |
| US-9428541-B2 | Substrate reduction therapy | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-30 | — | — | US | disclosed |
| WO-2016110702-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | ISIS INNOVATION LIMITED (GB) | 2016-07-14 | — | — | WO | disclosed |
| EP-0494850-A2 | Novel antiviral compounds | G.D. Searle & Co. (US) | 1992-07-15 | — | — | EP | disclosed |
| US-5003072-A | Viricides | G. D. SEARLE & CO. (US) | 1991-03-26 | — | — | US | disclosed |
| EP-0367748-A2 | Novel antiviral compounds | G.D. SEARLE & COMPANY (US) | 1990-05-09 | — | — | EP | disclosed |
| EP-0157603-A2 | 1, 3-Benzoxathiole derivatives, their use and their preparation | SANKYO COMPANY LIMITED (JP) | 1985-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125796-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | UGCG, SMPD1, SMPD4 | TP53 4540/4885SLC7A5 1626/4885ALDH1A1 1992/4885 |
| US-20100204162-A1 | SUBSTRATE REDUCTION THERAPY | GBA1, SPTLC2, NPC1L1 | TP53 4801/4885SLC7A5 722/4885ALDH1A1 1512/4885 |
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | GBA1, SPTLC2, NPC1L1 | TP53 4801/4885SLC7A5 722/4885ALDH1A1 1512/4885 |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | UGCG, GBA1, ENGASE | TP53 2200/4885SLC7A5 1667/4885ALDH1A1 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.